Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Diabetes Mellitus, Type 2 · Pharmacokinetic trial

Boehringer Ingelheim

Boehringer Ingelheim drug portfolio — 113 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Website Investor relations
Binger Straße, Ingelheim am Rhein, Rhineland-Palatinate 55218, DE HQ
46,699 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Binger Straße, Ingelheim am Rhein, Rhineland-Palatinate 55218, DE
Employees
46,699
Programs
193
Drugs
113
Patents
25
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Drug Pipeline

Boehringer Ingelheim pipeline

Portfolio lens on 113 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.

Boehringer Ingelheim drug portfolio — 113 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Drug portfolio

113 compounds

  2. afatinib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Mechanism: Epidermal growth factor receptor erbB1 inhibitor.

    Mechanism
    Epidermal growth factor receptor erbB1 inhibitor

  3. amlodipine

    Cardiovascular system (C09)

    Cardiovascular system (C09) compound in Boehringer Ingelheim's portfolio. Mechanism: Voltage-gated L-type calcium channel blocker.

    Mechanism
    Voltage-gated L-type calcium channel blocker

  4. anti-

    Development asset linked to Boehringer Ingelheim in public FDA and regional records.

  5. antibody

    Development asset linked to Boehringer Ingelheim in public FDA and regional records.

  6. atezolizumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.

    Target
    Programmed cell death 1 ligand 1
    Mechanism
    Programmed cell death 1 ligand 1 inhibitor

  7. atra

    Development asset linked to Boehringer Ingelheim in public FDA and regional records.

  8. beam

    Development asset linked to Boehringer Ingelheim in public FDA and regional records.

  9. bi 201335

    Development asset linked to Boehringer Ingelheim in public FDA and regional records. Molecular target: Hepatitis C virus serine protease, NS3/NS4A.

    Target
    Hepatitis C virus serine protease, NS3/NS4A
    Mechanism
    Hepatitis C virus serine protease, NS3/NS4A inhibitor

  10. bosentan

    Cardiovascular system (C02)

    US regulatory status: approved. Molecular target: Endothelin receptor, ET-A/ET-B.

    Target
    Endothelin receptor, ET-A/ET-B
    Mechanism
    Endothelin receptor, ET-A/ET-B antagonist

  11. brigimadlin

    Development asset linked to Boehringer Ingelheim in public FDA and regional records.

  12. bupropion

    Development asset linked to Boehringer Ingelheim in public FDA and regional records. Mechanism: Dopamine transporter inhibitor.

    Mechanism
    Dopamine transporter inhibitor

  13. caffeine

    Nervous system (N06)

    US regulatory status: approved. Molecular target: Adenosine receptor.

    Target
    Adenosine receptor
    Mechanism
    Adenosine receptor antagonist

  14. calcium

    US regulatory status: approved.

  15. capecitabine

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    Thymidylate synthase inhibitor

  16. carbamazepine

    US regulatory status: approved. Molecular target: Sodium channel alpha subunit.

    Target
    Sodium channel alpha subunit
    Mechanism
    Sodium channel alpha subunit blocker

  17. carboplatin

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  18. carisoprodol

    US regulatory status: approved. Mechanism: Unknown.

    Mechanism
    Unknown

  19. cetuximab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Epidermal growth factor receptor.

    Target
    Epidermal growth factor receptor
    Mechanism
    Epidermal growth factor receptor erbB1 inhibitor

  20. chemotherapy

    Development asset linked to Boehringer Ingelheim in public FDA and regional records.

  21. cisplatin

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  22. combination

    Development asset linked to Boehringer Ingelheim in public FDA and regional records.

  23. control

    Development asset linked to Boehringer Ingelheim in public FDA and regional records.

  24. dabigatran

    Development asset linked to Boehringer Ingelheim in public FDA and regional records. Molecular target: Prothrombin.

    Target
    Prothrombin
    Mechanism
    Thrombin inhibitor

  25. dabigatran etexilate

    Blood and blood forming organs (B01)

    Blood and blood forming organs (B01) compound in Boehringer Ingelheim's portfolio. Mechanism: Thrombin inhibitor.

    Mechanism
    Thrombin inhibitor

  26. digoxin

    US regulatory status: approved. Molecular target: Sodium/potassium-transporting ATPase.

    Target
    Sodium/potassium-transporting ATPase
    Mechanism
    Sodium/potassium-transporting ATPase inhibitor

  27. docetaxel

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Tubulin.

    Target
    Tubulin
    Mechanism
    Tubulin inhibitor

  28. dose

    Development asset linked to Boehringer Ingelheim in public FDA and regional records.

  29. doxorubicin

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Boehringer Ingelheim's portfolio. Mechanism: DNA topoisomerase II alpha inhibitor.

    Mechanism
    DNA topoisomerase II alpha inhibitor

  30. durvalumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.

    Target
    Programmed cell death 1 ligand 1
    Mechanism
    Programmed cell death 1 ligand 1 inhibitor

  31. empagliflozin

    Alimentary tract and metabolism (A10)

    US regulatory status: approved. Molecular target: Sodium/glucose cotransporter 2.

    Target
    Sodium/glucose cotransporter 2
    Mechanism
    Sodium/glucose cotransporter 2 inhibitor

  32. endocrine

    Development asset linked to Boehringer Ingelheim in public FDA and regional records.

  33. enoxaparin sodium

    Blood and blood forming organs (B01)

    US regulatory status: approved. Molecular target: Antithrombin-III.

    Target
    Antithrombin-III
    Mechanism
    Antithrombin-III activator

  34. erythromycin

    US regulatory status: approved. Molecular target: Bacterial 70S ribosome.

    Target
    Bacterial 70S ribosome
    Mechanism
    Bacterial 70S ribosome inhibitor

  35. erythromycin lactobionate

    US regulatory status: approved. Molecular target: Bacterial 70S ribosome.

    Target
    Bacterial 70S ribosome
    Mechanism
    Bacterial 70S ribosome inhibitor

  36. esomeprazole

    Alimentary tract and metabolism (A02)

    Alimentary tract and metabolism (A02) compound in Boehringer Ingelheim's portfolio. Mechanism: Potassium-transporting ATPase inhibitor.

    Mechanism
    Potassium-transporting ATPase inhibitor

  38. ethinyl estradiol

    US regulatory status: approved. Molecular target: Estrogen receptor.

    Target
    Estrogen receptor
    Mechanism
    Estrogen receptor alpha agonist

  39. extended-release

    Development asset linked to Boehringer Ingelheim in public FDA and regional records.

  40. fluorouracil

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    Thymidylate synthase inhibitor

  41. formulation

    Development asset linked to Boehringer Ingelheim in public FDA and regional records.

  42. furosemide

    Cardiovascular system (C03)

    US regulatory status: approved. Molecular target: Solute carrier family 12 member 1.

    Target
    Solute carrier family 12 member 1
    Mechanism
    Sodium-(potassium)-chloride cotransporter 2 inhibitor

  43. glucagon

    Systemic hormonal preparations (H04)

    US regulatory status: approved. Molecular target: Glucagon receptor.

    Target
    Glucagon receptor
    Mechanism
    Glucagon receptor agonist

  44. glucagon hydrochloride

    US regulatory status: approved. Molecular target: Glucagon receptor.

    Target
    Glucagon receptor
    Mechanism
    Glucagon receptor agonist

  45. group

    Development asset linked to Boehringer Ingelheim in public FDA and regional records.

  46. hema-

    Development asset linked to Boehringer Ingelheim in public FDA and regional records.

  47. hexachlorophene

    US regulatory status: approved. Molecular target: Enoyl-[acyl-carrier-protein] reductase [NADH] FabI.

    Target
    Enoyl-[acyl-carrier-protein] reductase [NADH] FabI
    Mechanism
    Bacterial enoyl-[acyl-carrier-protein] reductase inhibitor

  48. high-dose

    Development asset linked to Boehringer Ingelheim in public FDA and regional records.

  49. hydromorphone

    Development asset linked to Boehringer Ingelheim in public FDA and regional records. Mechanism: Mu opioid receptor agonist.

    Mechanism
    Mu opioid receptor agonist

  50. iclepertin

    Development asset linked to Boehringer Ingelheim in public FDA and regional records.

  51. immunotherapy

    Development asset linked to Boehringer Ingelheim in public FDA and regional records.

  52. infusion

    Development asset linked to Boehringer Ingelheim in public FDA and regional records.

  53. inhibitor

    Development asset linked to Boehringer Ingelheim in public FDA and regional records.

  54. injection

    Development asset linked to Boehringer Ingelheim in public FDA and regional records.

  55. intravenous

    Development asset linked to Boehringer Ingelheim in public FDA and regional records.

  56. investigator

    Development asset linked to Boehringer Ingelheim in public FDA and regional records.

  57. itraconazole

    US regulatory status: approved. Molecular target: Lanosterol 14-alpha demethylase.

    Target
    Lanosterol 14-alpha demethylase
    Mechanism
    Cytochrome P450 51 inhibitor

  58. ketorolac tromethamine

    US regulatory status: approved. Molecular target: Cyclooxygenase.

    Target
    Cyclooxygenase
    Mechanism
    Cyclooxygenase inhibitor

  59. levodopa + carbidopa

    Development asset linked to Boehringer Ingelheim in public FDA and regional records.

  60. linagliptin

    Alimentary tract and metabolism (A10)

    US regulatory status: approved. Molecular target: Dipeptidyl peptidase 4.

    Target
    Dipeptidyl peptidase 4
    Mechanism
    Dipeptidyl peptidase IV inhibitor

  61. low-dose

    Development asset linked to Boehringer Ingelheim in public FDA and regional records.

  62. matching

    Development asset linked to Boehringer Ingelheim in public FDA and regional records.

  63. metformin

    Development asset linked to Boehringer Ingelheim in public FDA and regional records. Mechanism: Mitochondrial complex I (NADH dehydrogenase) inhibitor.

    Mechanism
    Mitochondrial complex I (NADH dehydrogenase) inhibitor

  64. metoprolol

    Development asset linked to Boehringer Ingelheim in public FDA and regional records. Mechanism: Beta-1 adrenergic receptor antagonist.

    Mechanism
    Beta-1 adrenergic receptor antagonist

  65. midazolam

    Nervous system (N05)

    US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.

    Target
    GABA-A receptor; anion channel
    Mechanism
    GABA-A receptor; anion channel positive allosteric modulator

  67. nintedanib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Mechanism: Vascular endothelial growth factor receptor inhibitor.

    Mechanism
    Vascular endothelial growth factor receptor inhibitor

  68. nintedanib esylate

    US regulatory status: approved. Molecular target: Fibroblast growth factor receptor.

    Target
    Fibroblast growth factor receptor
    Mechanism
    Fibroblast growth factor receptor inhibitor

  69. nivolumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Programmed cell death protein 1.

    Target
    Programmed cell death protein 1
    Mechanism
    Programmed cell death protein 1 inhibitor

  70. olodaterol

    Development asset linked to Boehringer Ingelheim in public FDA and regional records. Mechanism: Beta-2 adrenergic receptor agonist.

    Mechanism
    Beta-2 adrenergic receptor agonist

  71. omeprazole

    US regulatory status: approved. Molecular target: Potassium-transporting ATPase.

    Target
    Potassium-transporting ATPase
    Mechanism
    Potassium-transporting ATPase inhibitor

  72. oxaliplatin

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  73. pembrolizumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Programmed cell death protein 1.

    Target
    Programmed cell death protein 1
    Mechanism
    Programmed cell death protein 1 inhibitor

  74. pemetrexed

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Dihydrofolate reductase.

    Target
    Dihydrofolate reductase
    Mechanism
    Thymidylate synthase inhibitor

  75. pemetrexed disodium

    US regulatory status: approved. Molecular target: Dihydrofolate reductase.

    Target
    Dihydrofolate reductase
    Mechanism
    Thymidylate synthase inhibitor

  76. pemetrexed sodium

    US regulatory status: approved. Molecular target: Dihydrofolate reductase.

    Target
    Dihydrofolate reductase
    Mechanism
    Thymidylate synthase inhibitor

  77. placebo

    Development asset linked to Boehringer Ingelheim in public FDA and regional records.

  78. powder

    Development asset linked to Boehringer Ingelheim in public FDA and regional records.

  79. pramipexole

    Nervous system (N04)

    Nervous system (N04) compound in Boehringer Ingelheim's portfolio. Mechanism: D2-like dopamine receptor agonist.

    Mechanism
    D2-like dopamine receptor agonist

  80. probenecid

    US regulatory status: approved. Molecular target: Solute carrier family 22 member 11.

    Target
    Solute carrier family 22 member 11
    Mechanism
    Solute carrier family 22 member 6 inhibitor

  81. repaglinide

    Alimentary tract and metabolism (A10)

    US regulatory status: approved. Molecular target: Sulfonylurea receptor 1, Kir6.2.

    Target
    Sulfonylurea receptor 1, Kir6.2
    Mechanism
    Sulfonylurea receptor 1, Kir6.2 blocker

  82. ribavirin

    Antiinfectives for systemic use (J05)

    US regulatory status: approved. Molecular target: Inosine-5'-monophosphate dehydrogenase 1.

    Target
    Inosine-5'-monophosphate dehydrogenase 1
    Mechanism
    Inosine-5'-monophosphate dehydrogenase 1 inhibitor

  83. rosuvastatin

    Development asset linked to Boehringer Ingelheim in public FDA and regional records. Mechanism: HMG-CoA reductase inhibitor.

    Mechanism
    HMG-CoA reductase inhibitor

  84. semaglutide

    Alimentary tract and metabolism (A10)

    US regulatory status: approved. Molecular target: Glucagon-like peptide 1 receptor.

    Target
    Glucagon-like peptide 1 receptor
    Mechanism
    Glucagon-like peptide 1 receptor agonist

  85. solution

    Development asset linked to Boehringer Ingelheim in public FDA and regional records.

  86. solvent

    Development asset linked to Boehringer Ingelheim in public FDA and regional records.

  87. spesolimab

    Antineoplastic and immunomodulating agents (L04)

    Antineoplastic and immunomodulating agents (L04) compound in Boehringer Ingelheim's portfolio. Molecular target: IL36 receptor.

    Target
    IL36 receptor
    Mechanism
    IL36 receptor antagonist

  88. standard

    Development asset linked to Boehringer Ingelheim in public FDA and regional records.

  89. statin

    Development asset linked to Boehringer Ingelheim in public FDA and regional records.

  90. stro-

    Development asset linked to Boehringer Ingelheim in public FDA and regional records.

  91. subcutaneous

    Development asset linked to Boehringer Ingelheim in public FDA and regional records.

  92. tablet

    Development asset linked to Boehringer Ingelheim in public FDA and regional records.

  93. tablets

    Development asset linked to Boehringer Ingelheim in public FDA and regional records.

  94. targeted

    Development asset linked to Boehringer Ingelheim in public FDA and regional records.

  95. telmisartan

    Cardiovascular system (C09)

    US regulatory status: approved. Molecular target: Type-1 angiotensin II receptor.

    Target
    Type-1 angiotensin II receptor
    Mechanism
    Type-1 angiotensin II receptor antagonist

  98. tenecteplase

    Blood and blood forming organs (B01)

    US regulatory status: approved. Molecular target: Tissue-type plasminogen activator.

    Target
    Tissue-type plasminogen activator
    Mechanism
    Tissue-type plasminogen activator exogenous protein

  99. therapy

    Development asset linked to Boehringer Ingelheim in public FDA and regional records.

  100. tiotropium

    Development asset linked to Boehringer Ingelheim in public FDA and regional records. Mechanism: Muscarinic acetylcholine receptor M3 antagonist.

    Mechanism
    Muscarinic acetylcholine receptor M3 antagonist

  102. tiotropium bromide

    US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M3.

    Target
    Muscarinic acetylcholine receptor M3
    Mechanism
    Muscarinic acetylcholine receptor M3 antagonist

  103. tipranavir

    Antiinfectives for systemic use (J05)

    US regulatory status: approved. Molecular target: Human immunodeficiency virus type 1 protease.

    Target
    Human immunodeficiency virus type 1 protease
    Mechanism
    Human immunodeficiency virus type 1 protease inhibitor

  104. tocilizumab

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Interleukin-6 receptor subunit alpha.

    Target
    Interleukin-6 receptor subunit alpha
    Mechanism
    Interleukin-6 receptor alpha subunit inhibitor

  105. trastuzumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Receptor tyrosine-protein kinase erbB-2.

    Target
    Receptor tyrosine-protein kinase erbB-2
    Mechanism
    Receptor protein-tyrosine kinase erbB-2 inhibitor

  106. trastuzumab deruxtecan

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Boehringer Ingelheim's portfolio. Molecular target: DNA topoisomerase 1.

    Target
    DNA topoisomerase 1
    Mechanism
    DNA topoisomerase I inhibitor

  107. trastuzumab emtansine

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Boehringer Ingelheim's portfolio. Molecular target: Receptor tyrosine-protein kinase erbB-2.

    Target
    Receptor tyrosine-protein kinase erbB-2
    Mechanism
    Tubulin inhibitor

  108. treatment

    Development asset linked to Boehringer Ingelheim in public FDA and regional records.

  109. ustekinumab

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Interleukin-12.

    Target
    Interleukin-12
    Mechanism
    Interleukin-23 inhibitor

  110. vaccine

    Development asset linked to Boehringer Ingelheim in public FDA and regional records.

  111. warfarin

    Development asset linked to Boehringer Ingelheim in public FDA and regional records. Mechanism: Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor.

    Mechanism
    Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor

  112. zanidatamab

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Boehringer Ingelheim's portfolio. Molecular target: Receptor tyrosine-protein kinase erbB-2.

    Target
    Receptor tyrosine-protein kinase erbB-2
    Mechanism
    Receptor protein-tyrosine kinase erbB-2 inhibitor

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.